

(51) International Patent Classification:
A61K 38/10 (2006.01)

(21) International Application Number:

PCT/US2015/053558

(22) International Filing Date:

1 October 2015 (01.10.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/058,506	1 October 2014 (01.10.2014)	US
62/058,510	1 October 2014 (01.10.2014)	US
62/149,257	17 April 2015 (17.04.2015)	US
62/192,934	15 July 2015 (15.07.2015)	US

(71) Applicant: **PROTAGONIST THERAPEUTICS, INC.**
[US/US]; 521 Cottonwood Drive, Suite A, Milpitas, California 95035 (US).(72) Inventors: **BHANDARI, Ashok**; 2629 Lotus Street, Pleasanton, California 94588 (US). **PATEL, Dinesh V.**; 45109 Cougar Circle, Fremont, California 94539 (US). **ZEMEDE, Genet**; 1417 Glacier Drive, San Jose, California 95118 (US). **MATTHEAKIS, Larry C.**; 20612 Sunrise Drive, Cupertino, California 95014 (US). **LIU, David**; c/o Protagonist Therapeutics, Inc., 521 Cottonwood Drive, Suite A, Milpitas, California 95035 (US).(74) Agents: **LAHERTY, Carol** et al.; Cooley LLP, 1299 Pennsylvania Avenue, NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

[Continued on next page]


(54) Title: NOVEL $\alpha 4\beta 7$ PEPTIDE MONOMER AND DIMER ANTAGONISTS

FIG. 1

(57) Abstract: The invention relates to peptide dimer compounds and peptide monomer compounds that potentially inhibit binding of u4137 to the mucosal address in cell adhesion molecule (MAdCAM) in vivo, possess high selectivity against ct431 binding, and have high stability under gastrointestinal conditions. The present invention has been developed in response to the present state of the art, and in particular, in response to the problems and needs in the art that have not yet been fully solved by currently available integrin antagonists.



Published:

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))